Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (2)
  • c-Met/HGFR
    (2)
TargetMol | Tags By Application
  • ELISA
    (3)
  • Functional assay
    (3)
  • FACS
    (2)
  • FCM
    (1)
Filter
Search Result
Results for "

amivantamab

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    1
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    3
    TargetMol | Inhibitory_Antibodies
Amivantamab
JNJ-61186372, JNJ61186372
T9901A-15512171511-58-1
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
    Inquiry
    Amivantamab (FUT8-KO)
    T9901A-232
    Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, with FUT8 knocked out, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.
    • Inquiry Price
    Inquiry
    Size
    QTY
    Amivantamab (Anti-c-Met)
    JNJ61186372 (Anti-c-Met), JNJ-61186372 (Anti-c-Met), JNJ 61186372 (Anti-c-Met)
    T77110
    Amivantamab (Anti-c-Met) is a human antibody that recognizes the MET proto-oncogene (MET) and can be used in cancer-related research.
    • $289
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot